Co-Diagnostics, Inc. CODX shares are trading higher on Thursday.

The company announced that OralDNA Labs, a CLIA-certified laboratory, have validated a COVID-19 PCR test based on the company's patented CoPrimer technology for use with saline oral rinse samples.

Co-Diagnostics a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules.

Co-Diagnostics shares were trading up 37.05% at $13.02 at the time of publication Thursday. The stock has a 52-week high of $21.75 and a 52-week low of 69 cents.

Related Links:

3 Frontrunners In COVID-19 Vaccine Development: What You Need To Know

Co-Diagnostics To Provide Coronavirus Tests To Certified US Labs After FDA Policy Change